Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia

NCT00254423 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia

Interventions

DRUG: Dasatinib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]